This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).
AVNS Stock Gains Post Q1 Earnings & Revenue Beat, Gross Margin Down
by Zacks Equity Research
Strength in Avanos' SNS segment drives its first-quarter 2025 performance despite global macroeconomic challenges.
FMS Stock Up as Q1 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Fresenius Medical's first-quarter results showcase a strong segmental performance, along with reiterating its 2025 outlook for revenue growth.
CLOV Stock Rises as Q1 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Clover Health's first-quarter 2025 results continue to benefit from the strength of its strong member retention. A decline in operating loss bodes well.
MASI Stock Slips Despite Q1 Earnings and Revenue Beat, Margins Expand
by Zacks Equity Research
Masimo's first-quarter 2025 results continue to benefit from the strength in its Healthcare businesses despite tariff-related uncertainties.
Bio-Techne Q3 Earnings & Revenues Top Estimates, Stock Up in Premarket
by Zacks Equity Research
TECH registers continued growth momentum across its Diagnostics & Spatial Biology segment in third-quarter fiscal 2025.
CRL Q1 Earnings & Revenues Beat Estimates, Stock Rises, '25 View Up
by Zacks Equity Research
Charles River delivers better-than-expected earnings and revenues in the first quarter of 2025.
MYGN Q1 Earnings Top Estimates, Stock Down on Weak 2025 Outlook
by Zacks Equity Research
Myriad Genetics delivers a narrower-than-expected loss in the first quarter of 2025.
HIMS Stock Dips Pre-Market Despite Q1 Earnings Beat, Gross Margin Down
by Zacks Equity Research
Hims & Hers' first-quarter 2025 performance reflects continued strength in its online revenue channel on the back of solid product demand and an increasing subscriber base.
INSP Stock Gains Following Q1 Earnings Beat, Gross Margin Contracts
by Zacks Equity Research
Inspire Medical's first-quarter 2025 performance reflects increased market penetration in existing centers and expansion into new territories and centers, along with strong domestic results.
The Zacks Analyst Blog Highlights GE Healthcare, Johnson & Johnson, Abbott and Boston Scientific
by Zacks Equity Research
GE Healthcare, Johnson & Johnson, Abbott and Boston Scientific are part of the Zacks top Analyst Blog.
Integra Q1 Earnings Miss Estimates, Stock Down, '25 EPS Outlook Cut
by Zacks Equity Research
IART's first-quarter 2025 earnings lag the consensus mark. Q2 revenue projections are bleak.
MedTechs Adjust 2025 Outlook Amid Tariffs: What Investors Need to Know
by Urmimala Biswas
Most of the MedTech players have adjusted their 2025 forecasts in response to rising tariff pressure.
Henry Schein Q1 Earnings Top Estimates, Revenues Miss, Stock Falls
by Zacks Equity Research
HSIC ends the first quarter of 2025 on a mixed note.
If You Invested $1000 in Boston Scientific 10 Years Ago, This Is How Much You'd Have Now
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Zacks Investment Ideas feature highlights: Boston Scientific, Meta Platforms and Microsoft
by Zacks Equity Research
Boston Scientific, Meta Platforms and Microsoft have been highlighted in this Investment Ideas article.
EXAS Stock Up on Q1 Earnings & Revenue Beat, 2025 Sales View Raised
by Zacks Equity Research
Exact Sciences ends the first quarter of 2025 on a solid note.
Hologic Q2 Earnings & Revenues Top, '25 EPS View Lowered, Stock Down
by Zacks Equity Research
HOLX delivers earnings and revenue beat in the second quarter of fiscal 2025 amid macroeconomic turbulence.
These 3 Stocks Soared Following Strong Quarterly Results
by Derek Lewis
The 2025 Q1 earnings cycle is in full swing. And these three companies posted results that had investors pleased.
SRDX Stock Down Following Q2 Earnings Miss, Gross Margin Contracts
by Zacks Equity Research
Despite the strength in Pounce thrombectomy device platforms and strong IVD product sales, Surmodics' second-quarter fiscal 2025 results show weak performance.
OPK Stock Slips Following Q1 Earnings Miss, Gross Margin Expands
by Zacks Equity Research
Despite strength in OPKO Health's revenues from the transfer of intellectual property, the company reports an overall soft first-quarter 2025 performance.
BD Stock Falls in Pre-Market Despite Q2 Earnings Beat, Margins Down
by Zacks Equity Research
BDX's overall topline in the second quarter of fiscal 2025 continues to benefit from strength in its Medical segment and geographic performances.
ICON's Q1 Earnings Surpass Estimates, Revenues Lag, Stock Down
by Zacks Equity Research
ICLR posts mixed results in the first quarter of 2025 due to ongoing clinical development and market volatility.
CVS Q1 Earnings & Revenues Beat, '25 EPS View Raised, Stock Up
by Zacks Equity Research
CVS Health delivers earnings and revenue beat in the first quarter of 2025.
Earnings Season: 3 Companies Raising Guidance
by Derek Lewis
Raising guidance? In this uncertainty? These three companies say yes.
Labcorp Q1 Earnings Surpass Estimates, Revenues Miss, Stock Gains
by Zacks Equity Research
LH delivers better-than-expected earnings in the first quarter of 2025.